Suz12 inactivation causes activation of the PI3K/mTOR, VEGF/VEGFR and WNT signaling pathways. (A) Results of overrepresentation enrichment analysis of the KEGG canonical pathways in the set of upregulated genes in JAK3(M511I)+Suz12gRNA leukemias (J+S1 vs J), ranked according to lowest false discovery rate (FDR). The number of genes within a pathway is indicated in brackets. (B) Similar analysis as in A, but now with the canonical pathways. (C-E) Drug dose response curves showing viability of (leukemia) cells in response to 24 hours of treatment with increasing concentrations of PI3K/mTOR inhibitor dactolisib (C), VEGFR inhibitor sunitinib (D), and WNT inhibitor PKF118-310 (E). HSPC, wild-type hematopoietic stem and progenitor cells; Thy, wild-type thymocytes. For all drug dose response curves, percentage viability is defined as percentage surviving cells relative to DMSO concentration. GI50 values are shown.